Latest News and Press Releases
Want to stay updated on the latest news?
-
In data presented at SABCS23, DCISionRT changed radiation therapy decisions in 41% of DCIS patients
-
LAGUNA HILLS, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced study...
-
SEATTLE, WA--(Marketwired - Sep 18, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that it has entered into a nationwide distribution agreement with...
-
SEATTLE, WA--(Marketwired - Sep 6, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, will display its ForeCYTE Breast Health Test at the 7th annual Breast Cancer...
-
SEATTLE, WA--(Marketwired - Aug 14, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company™, today announced its second quarter 2013 financial results and corporate...
-
SEATTLE, WA--(Marketwired - Aug 6, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, today announced that it will issue financial results and corporate highlights for...
-
SEATTLE, WA--(Marketwired - Aug 5, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, said that the new ASCO clinical practice guideline for the use of pharmacologic...
-
SEATTLE, WA--(Marketwired - May 23, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, will display its ForeCYTE Breast Health Test at the 2013 American Society of...
-
SEATTLE, WA--(Marketwired - Apr 23, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, believes that new recommendations published on April 16 by the U.S. Preventative...
-
SEATTLE, WA--(Marketwired - Apr 23, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that Kyle Guse, CFO and General Counsel, will present the...